AMT Receives a Third of €3.3M EU Grant for Clinical Development of Gene Therapy - Gilde Healthcare

AMT Receives a Third of €3.3M EU Grant for Clinical Development of Gene Therapy

February 1, 2011

Amsterdam Molecular Therapeutics (AMT) will receive €1.1 million (about $1.5 million) of a €3.3 million (approximately $4.5 million) grant being awarded by the European Union 7th Framework Program (FP7) to the AIPGENE consortium, which is working to develop a gene therapy product for treating acute intermittent porphyria (AIP).

As part of the consortium AMT has commercialization rights to the gene therapy product, AMT-021, and projects patient enrolment into a clinical trial could start in 2012.  It says the grant will cover development costs of the product to completion of Phase I/II trials.

AMT-021 is designed to deliver a normal version of the porphobilinogen deaminase (PBDG)  liver protein gene that is mutated in AIP. AMT says its studies have already shown treatment using AMT-021 results in normalization of the PBGD protein in an animal model of AIP as well as prevents the occurrence of attacks and significantly ameliorates the neuropathy that otherwise occurs in untreated animals. The firm in addition notes that work by FIMA (Fundación para la Investigatión Médica Aplicada), which is leading the multinational AIPGENE consortium, has demonstrated that gene expression in the liver will persist for over a year using AAV-mediated delivery methods similar to that used for AMT-021.

Gilde Healthcare company Volta Medical announces positive results from transatlantic trial on AI-assisted ablation for persistent atrial fibrillation

TAILORED-AF randomized controlled trial (RCT) findings demonstrated superiority in freedom from atrial fibrillation (AF) at 12 months from a tailored cardiac ablation guided by artificial intelligence (AI) when compared to pulmonary vein isolation (PVI) alone....
May 21, 2024

Gilde Healthcare co-leads $100M equity financing in Karius

Karius®, Inc., a world leader in genomic diagnostics for infectious disease, today announced it has secured $100 million in Series C funding. The round was co-led by Gilde Healthcare, Khosla Ventures and 5AM Ventures, and...
May 2, 2024

Gilde Healthcare company Ablative Solutions demonstrates Significant Reduction in Blood Pressure meeting its primary endpoint in Pivotal Trial

Ablative Solutions, Inc., announced that primary trial results from the TARGET BPI Pivotal Trial, evaluating alcohol-mediated renal denervation with the Peregrine SystemTM Kit, were presented as a Late-Breaking Clinical Trial at the American College of...
April 11, 2024